Biosimilars and Biologics Market to Reach US$1,773.77 Billion by 2033 as High-Cost Specialty Therapies and Affordability Pressure Redefine Global Treatment Access

NEW YORK, May 24, 2026 - According to DataM Intelligence, the global Biosimilars and Biologics Market reached US$531.45 billion in 2024 and is expected to reach US$1,773.77 billion by 2033, growing at a CAGR of 14.4% during 2025 to 2033. The market is segmented by type into biologics and biosimilars, and by application into oncology, autoimmune diseases, chronic diseases, infectious diseases, neurology, ophthalmology and others.

The global biosimilars and biologics market is entering a high-value expansion cycle as healthcare systems balance the clinical power of biologic therapies with the growing need for affordable alternatives. On a growth-multiple basis, the market is expected to expand nearly 3.34x by 2033, positioning biosimilars and biologics as one of the most commercially important segments in global specialty medicine.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/biosimilars-and-biologics-market?kailas

Why Biosimilars and Biologics Is a Highly Sellable Market

The biosimilars and biologics market is highly sellable because it combines two powerful healthcare forces: biologics are high-cost, high-impact therapies for serious diseases, while biosimilars support affordability, competition and improved patient access. Biologics are used in complex treatment areas such as cancer, autoimmune diseases, chronic disorders, infectious diseases, neurology and ophthalmology, creating a broad demand base across specialty care. Biosimilars, meanwhile, offer a competitive pathway once reference biologics lose exclusivity, helping reduce cost pressure on patients, payers and healthcare systems.

The market's strength is also supported by regulatory momentum. The FDA describes biosimilars as products approved based on comparison to an FDA-approved biologic, and the agency continues to provide scientific and regulatory advice to bring safe and effective biosimilars to market. The FDA has also announced actions intended to make biosimilar development faster and less costly, describing biosimilars as lower-cost alternatives to biologic drugs used to treat serious and chronic diseases.

Biologics Remain Essential for Complex Chronic and Specialty Diseases

Biologics have become central to modern specialty medicine because they are designed to treat complex diseases through targeted biological mechanisms. DataM Intelligence notes that demand for biosimilars and biologics is being driven by increasing chronic disease prevalence, aging populations, technological advancement and the need to make healthcare more affordable. These therapies are especially relevant in conditions that often require long-term treatment, including cancer, diabetes, autoimmune disorders and other chronic diseases.

The aging population strengthens this demand foundation. DataM Intelligence cites WHO data showing that by 2030, 1 in 6 people globally will be aged 60 years or older, with the population aged 60 and above expected to increase from 1 billion in 2020 to 1.4 billion in 2030. By 2050, the number of people aged 60 and older is expected to double to 2.1 billion, increasing demand for advanced treatments while intensifying pressure on healthcare budgets.

Biosimilars Create the Affordability and Competition Advantage

Biosimilars are commercially important because they address one of the biggest barriers in biologics: cost. Cancer biologics, autoimmune biologics and other specialty therapies can be prohibitively expensive, limiting access for patients and creating budget pressure for healthcare systems. DataM Intelligence highlights that biosimilars can offer similar efficacy and safety at a lower cost, supporting more sustainable treatment access, particularly in oncology.

FDA's recent policy direction further strengthens this market logic. The agency announced action to simplify biosimilarity studies and reduce unnecessary clinical testing, with the goal of making biosimilar medicines faster and less costly to develop. This regulatory direction reinforces the commercial opportunity for biosimilars as competition-focused alternatives to expensive biologic therapies.

Oncology Holds 31.27% Market Share as Biosimilars Expand Cancer Treatment Access

Oncology is expected to hold 31.27% of the biosimilars and biologics market share in 2024, making it a leading application segment. DataM Intelligence notes that biosimilars in oncology have gained acceptance because they undergo rigorous clinical trials to demonstrate equivalence to reference biologics. As physicians and patients become more comfortable with oncology biosimilars through clinical evidence and real-world data, adoption is expected to strengthen further.

The oncology opportunity is particularly strong because many cancer biologics are high-cost therapies used across chemotherapy support, targeted treatment and immuno-oncology-linked care pathways. DataM Intelligence lists biosimilars linked to cancer-related reference products such as bevacizumab, rituximab, trastuzumab, filgrastim, pegfilgrastim, epoetin alfa and denosumab, showing how biosimilar competition is expanding across multiple oncology and supportive care categories.

Autoimmune, Ophthalmology and Chronic Disease Applications Strengthen Recurring Demand

The market is not dependent on oncology alone. Autoimmune diseases, chronic diseases, infectious diseases, neurology and ophthalmology all create strong demand for biologic and biosimilar therapies. Biologics are often used in chronic immune-mediated diseases where patients require long-term treatment, making recurring therapy demand a major commercial driver. Biosimilars can then enter these high-cost categories and support payer preference, access expansion and treatment continuity.

This recurring demand gives the market a highly durable structure. Patients with autoimmune disorders, chronic inflammatory diseases, ophthalmic conditions and certain neurologic diseases may require ongoing biologic treatment over years. As biosimilars become available for more reference biologics, the market can benefit from both premium biologic innovation and cost-competitive biosimilar expansion.

FDA Approvals Signal a Rapidly Expanding Biosimilar Landscape

Recent U.S. biosimilar approvals reinforce the growth narrative. DataM Intelligence lists multiple recently FDA-approved biosimilar products, including Jobevne for Avastin, Omlyclo for Xolair, Osenvelt and Stoboclo for Prolia, Merilog for Novolog and Avtozma for Actemra, among others. These approvals span oncology, immunology, bone health and metabolic care, showing that biosimilar competition is widening across high-value biologic categories.

Interchangeability also adds a competitive layer. The FDA explains that an interchangeable biological product is a biosimilar that meets additional requirements and may be substituted for the reference product at the pharmacy, depending on state pharmacy laws. This designation can support broader patient access and strengthen commercial uptake in selected markets.

North America Holds 42.18% Market Share

North America is expected to dominate the global biosimilars and biologics market with a 42.18% share in 2024. DataM Intelligence attributes the region's leadership to aging populations, higher prevalence of cancer, cardiovascular conditions and autoimmune diseases, strong biologics demand and the growing need for affordable biosimilar alternatives.

The region also benefits from a defined FDA biosimilar approval pathway. DataM Intelligence notes that the Biologics Price Competition and Innovation Act supports biosimilar approvals and helps facilitate market entry. Recent approvals, including Biocon Biologics' Jobevne, a biosimilar to Avastin, are helping accelerate North American market growth.

Regulatory Complexity Remains a Barrier, but Also Protects Market Quality

Despite strong growth prospects, regulatory complexity remains a key restraint. DataM Intelligence notes that biosimilars face demanding approval requirements because they must demonstrate safety, efficacy and biosimilarity to the reference biologic. Regulatory bodies such as the FDA and EMA require comprehensive evidence, including analytical, animal and clinical data, which can make development lengthy and expensive.

This complexity, however, also reinforces market credibility. Biosimilars are not simple generics; they are complex biological products requiring rigorous development and regulatory review. Strong standards help build confidence among physicians, patients and payers, supporting long-term adoption as more biosimilars prove safety, effectiveness and real-world performance.

Competitive Landscape: Global Biopharma Leaders Compete on Innovation, Access and Affordability

The global biosimilars and biologics market includes major companies such as Amgen Inc., Johnson & Johnson, Biogen Inc., Teva Pharmaceutical Industries Limited, Biocon Biologics Inc., Pfizer Inc., Celltrion, Inc., Samsung Bioepis, AbbVie Inc. and Boehringer Ingelheim International GmbH. Emerging players include Eli Lilly and Company, Sanofi S.A., Fresenius Kabi AG, Coherus BioSciences Inc., Alvotech S.A., Polpharma Biologics S.A., Formycon AG and Hexal AG.

Recent developments highlight competitive intensity. DataM Intelligence reports FDA approvals in 2025 for denosumab biosimilars from Fresenius Kabi, omalizumab biosimilar OMLYCLO from Celltrion, and denosumab biosimilars from Celltrion and Samsung Bioepis. These approvals show how biosimilar competition is moving across immunology, osteoporosis, oncology and bone health categories.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biosimilars-and-biologics-market?kailas

Strategic Outlook: Biosimilars and Biologics Become a Defining Market for Specialty Care Access

The biosimilars and biologics market is positioned for strong long-term growth because it addresses two critical healthcare priorities at once: advanced treatment innovation and affordability. Biologics remain essential for serious and complex diseases, while biosimilars create competition that can reduce cost pressure and improve access. With the market projected to rise from US$531.45 billion in 2024 to US$1,773.77 billion by 2033, this category is becoming one of the most valuable and commercially durable segments in global pharmaceuticals.

The next phase of growth will be shaped by biologic innovation, biosimilar approvals, oncology adoption, autoimmune treatment demand, payer preference, interchangeability, patent expirations, real-world evidence and regional access expansion. Because biologics are high-cost therapies and biosimilars support affordability and market competition, this market stands out as a highly sellable, access-driven and strategically important healthcare category through 2033.

About the Report

The Biosimilars and Biologics Market report by DataM Intelligence analyzes the market by type, application and region. Type coverage includes biologics and biosimilars. Application coverage includes oncology, autoimmune diseases, chronic diseases, infectious diseases, neurology, ophthalmology and others across North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. The report includes market size and forecast, competitive analysis, unmet needs, regulatory compliance, opportunity analysis, partner identification and strategic market intelligence.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.